NL-OMON43097已完成不适用
A SINGLE DOSE, RANDOMIZED, OPEN-LABEL, 4-WAY CROSSOVER STUDY TO ASSESS THE SAFETY, TOLERABILITY AND PHARMACOKINETICS OF ESKETAMINE (ORAL TABLET OF 20 MG AND 100 MG, ORAL SOLUTION OF 20 MG AND IV INFUSION OF 20 MG) IN HEALTHY VOLUNTEERS. - Esketamine safety and pharmacokinetics study.
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 16
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 64（—）
入选标准
- •healthy male or female
- •18-55 years, inclusive
- •BMI 19.0 - 29.0 kg/m2, inclusive
- •at least 60 kg or more
- •non smoking
排除标准
- •Suffering from hepatitis B, hepatitis C, cancer or HIV/AIDS. In case of participation in another drug study within 90 days before the start of this study or being a blood donor within 60 days from the start of the study. In case of donating more than 1.5 liters of blood in the 10 months prior the start of this study.
研究者
相似试验
已完成
不适用
A Single-Dose, Open-Label, Randomized, 4-Way Crossover Pivotal Study to Assess the Bioequivalence of Canagliflozin when Administered as the Monohydrate form to the Hemihydrate form in Healthy Adult Subjects under Fasted Conditionsglucose-lowering therapyglycemic control10018424NL-OMON42409Janssen-Cilag44
进行中（未招募）
不适用
A SINGLE-DOSE, OPEN-LABEL, RANDOMIZED, 2-WAY CROSS-OVER, CLINICAL PHARMACOLOGY STUDY OF CHF 1535 50/6 NEXT DPI® (FIXED COMBINATION OF BECLOMETASONE DIPROPIONATE 50 µg PLUS FORMOTEROL FUMARATE 6 µg ) VERSUS THE FREE COMBINATION OF LICENSED BECLOMETASONE DPI AND FORMOTEROL DPI IN ASTHMATIC CHILDREEUCTR2011-001208-36-DKChiesi Farmaceutici S.p.A26
已完成
不适用
An Open-Label, Single Dose, 4-Period, 4-Way Randomized Crossover Study to Evaluate the Pharmacokinetics of Preliminary Market Formulations of MK-8408 in Healthy Adult Subjects.NL-OMON40769Merck Sharp & Dohme (MSD)32
尚未招募
不适用
An Open-Label, Balanced, Randomized, Single-Dose, Four-Treatment, Four-Period, Four- Sequence, Four-Way Crossover Study of Oral Bioavailability ofSundalp/Micellon, in Healthy, Adult, Human Subjects Under Fasting Conditions.CTRI/2022/02/040335Pharmabase SA
已完成
不适用
A SINGLE-CENTER, SINGLE-DOSE, OPEN-LABEL, FOUR-WAY-CROSSOVER STUDY TO EVALUATE THE PHARMACOKINETIC PROFILE OF THE HP-5000 PATCH (DICLOFENAC SODIUM TRANSDERMAL DRUG DELIVERY SYSTEM) FOLLOWING 24-HOUR APPLICATION COMPARED TO FLECTOR® AND VOLTAREN® 100 MG IN HEALTHY ADULT MALE AND FEMALE SUBJECTS UNDER FASTING CONDITIONSontstekingeninflammationNL-OMON37576oven Pharmaceuticals, Inc.18